Autotaxin
(ATX) is a secreted phosphodiesterase that has been implicated
in a remarkably wide array of pathologies, especially in fibrosis
and cancer. While ATX inhibitors have entered the clinical arena,
a validated probe for positron emission tomography (PET) is currently
lacking. With the aim to develop a suitable ATX-targeted PET radioligand,
we have synthesized a focused library of fluorinated imidazo[1,2-a]pyridine derivatives, determined their inhibition constants,
and confirmed their binding mode by crystallographic analysis. Based
on their promising in vitro properties, compounds 9c, 9f, 9h, and 9j were
radiofluorinated. Also, a deuterated analog of [18F]9j, designated as [18F]ATX-1905 ([18F]20), was designed and proved to be highly stable against in vivo radiodefluorination compared with [18F]9c, [18F]9f, [18F]9h, and [18F]9j. These results
along with in vitro and in vivo studies
toward ATX in a mouse model of LPS-induced liver injury suggest that
[18F]ATX-1905 is a suitable PET probe for the non-invasive
quantification of ATX.